ME Therapeutics Holdings Inc. (CSE:METX)
Canada flag Canada · Delayed Price · Currency is CAD
2.270
-0.230 (-9.20%)
At close: Feb 9, 2026

ME Therapeutics Holdings Balance Sheet

Millions CAD. Fiscal year is Sep - Aug.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '25 Aug '25 Aug '24 Aug '23 Aug '22 Aug '21
Cash & Equivalents
1.191.351.50.650.080.07
Short-Term Investments
0.060.06----
Cash & Short-Term Investments
1.251.41.50.650.080.07
Cash Growth
-6.06%-6.27%131.28%736.35%5.91%47.00%
Other Receivables
0.050.070.020.010.020
Receivables
0.050.070.020.010.020
Prepaid Expenses
0.020.030.030.020-
Total Current Assets
1.321.51.540.670.10.08
Property, Plant & Equipment
0.220.250000
Other Intangible Assets
000000
Other Long-Term Assets
0.010.01----
Total Assets
1.551.761.540.670.10.08
Accounts Payable
0.130.160.050.110.020.03
Accrued Expenses
0.020.010.02---
Short-Term Debt
----0.13-
Current Portion of Long-Term Debt
---0.04--
Current Portion of Leases
0.060.06----
Other Current Liabilities
0.010.01-00.020.01
Total Current Liabilities
0.220.250.060.150.170.03
Long-Term Debt
----0.060.06
Long-Term Leases
-0.01----
Total Liabilities
0.220.260.060.150.230.09
Common Stock
8.928.596.114.520.510.51
Retained Earnings
-10.02-9.73-8.54-7.24-0.72-0.57
Comprehensive Income & Other
2.432.643.93.240.080.04
Shareholders' Equity
1.331.51.480.52-0.13-0.02
Total Liabilities & Equity
1.551.761.540.670.10.08
Total Debt
0.060.07-0.040.190.06
Net Cash (Debt)
1.191.331.50.61-0.120.01
Net Cash Growth
-2.22%-11.06%146.52%--34.62%
Net Cash Per Share
0.040.050.060.04-0.010.00
Filing Date Shares Outstanding
30.0530.0525.1923.566.086.08
Total Common Shares Outstanding
30.0529.5925.1923.566.086.08
Working Capital
1.11.261.480.52-0.070.04
Book Value Per Share
0.040.050.060.02-0.02-0.00
Tangible Book Value
1.331.51.480.52-0.13-0.02
Tangible Book Value Per Share
0.040.050.060.02-0.02-0.00
Machinery
0.190.190000
Leasehold Improvements
0.030.03----
Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.